MetaVia
Manufacturing · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
545 Concord Ave Ste 210, Cambridge, Mass...Phone Number
(857) 702-9600Website
www.metaviatx.comRevenue
-Stock Symbol
MTVAIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About MetaVia
MetaVia formerly known as NeuroBo Pharmaceuticals is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity and DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH).Explore more
MetaVia Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MetaVia your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
MetaVia, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when MetaVia launches new products
Check if MetaVia has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on MetaVia recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at MetaVia
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if MetaVia had a recent Job posting/layoffs
Funding: Get notified immidiatlly once MetaVia has new funding data
Website visits: Recent activity has been detected on your website
Check out if MetaVia is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined MetaVia as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
MetaVia is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
MetaVia is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about MetaVia.
Most Recent Scoops
Earnings
Earnings, Finance
Earnings
Earnings, Finance
Product Launch
MetaVia has reported promising data from a four-week multiple ascending dose phase one trial of its obesity therapy DA-1726, a GLP-1 glucagon dual agonist.
Medical Research, Pharmaceuticals, Clinical Operations
Project
reported significant waist reduction results for its obesity therapy DA-1726, with a maximum reduction of 3.9 inches and a mean reduction of 1.4 inches in four weeks, with effects sustained one month after the last dose.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Product Development, Pharmaceuticals, Clinical Operations
MetaVia News & Media
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference
CAMBRIDGE, Mass., June 4, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H. Woodworth, Chief Financial...MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH
48 mg Cohort Achieved Up to 9.1% Mean Body Weight Reduction at Day 54 Without Evidence of Plateau Exploratory FibroScan Assessments Demonstrated Early Liver-Related Improvements Ongoing Phase 1 Part 3a/3b Titration Studies Continue to Evaluate Extended Treatment at Higher-Dose Levels...MetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions
Three Late-Breaking Posters Highlight DA-1726, a GLP-1/Glucagon Dual Agonist, and Vanoglipel, a GPR119 Agonist CAMBRIDGE, Mass., May 18, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today...MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update
48 mg Phase 1 Data Demonstrated Potential Best-in-Class Profile for DA-1726 with 9.1% Weight Loss, Improved Glucose Control and Direct Liver Benefit Key Milestone Achieved with Dosing of the First Patient in Phase 1 Part 3 16-Week Titration Study Evaluating 48 mg (1-Step) and 64 mg...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding MetaVia
Sign Up For FreeTo access detailed company insights
MetaVia formerly known as NeuroBo Pharmaceuticals is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity and DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH).... Read More
